Rahmer Peter sold $14K of RLAY
Rahmer Peter (See remarks) sold 753 shares of Relay Therapeutics, Inc. (RLAY) at $18.62 on 2026-10-28.
How this was made
The 30-second read
Why it matters
While the transaction size is trivial, it offers a data point for monitoring insider sentiment. The retained holdings remain substantial, mitigating concern.
Market read
A routine insider sale with limited material impact; primarily of interest to short‑term traders monitoring insider activity.
What to watch
No 10b5‑1 plan and the officer retains a large stake, indicating continued confidence despite the sale.
Background
Form 4 filings provide the first public record of insider transactions. This filing reports a modest sale by an officer of Relay Therapeutics.
Ticker impact
Officer Rahmer Peter sold 753 shares of Relay Therapeutics for $14,020, a direct insider sale disclosed on Form 4.
potential slight downward pressure as the market prices the insider sell
Small transaction size ($14K) from an officer, no 10b5‑1 plan, suggests a discretionary sell; traders may watch for short‑term dip.
Market effects
Minimal impact on the broader biotech sector; insider activity is isolated.
No regional effect; confined to Relay Therapeutics shareholders.
Low global relevance; the filing is a routine disclosure.
Counterpoint
The sale could be unrelated to company outlook; investors may ignore the small sell.
Key entities
- CompanyRelay Therapeutics, Inc.
Biopharmaceutical company developing precision medicines.
- OfficerRahmer Peter
Company officer who executed the share sale.
